Linear mixed model for heritability estimation that explicitly addresses environmental variationEffect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in UgandaCD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive UgandansImmune activation alters cellular and humoral responses to yellow fever 17D vaccineHigh incidence of HIV-1 infection in a general population of fishing communities around Lake Victoria, UgandaGeographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysisCorrection: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-AnalysisEvidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialVirological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in UgandaCorrection: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialLong-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaInternational health research monitoring: exploring a scientific and a cooperative approach using participatory action researchCommon variants associated with plasma triglycerides and risk for coronary artery diseaseHIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmissionDiscovery and refinement of loci associated with lipid levels.HIV in Africa (Communication arising): chemokine-receptor genes and AIDS risk.Taking forward the World TB Day 2016 theme 'Unite to End Tuberculosis' for the WHO Africa Region.EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa.African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent.Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans.CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Hepatitis B serological markers and plasma DNA concentrations.The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.Pregnancy, parturition and preeclampsia in women of African ancestryEquivalence of ELISpot assays demonstrated between major HIV network laboratoriesFirst trial of the HIV-1 vaccine in Africa: Ugandan experience.Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans.Short-course antiretroviral therapy in primary HIV infection.Research capacity. Enabling the genomic revolution in Africa.Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.The relationship between HIV type 1 disease progression and V3 serotype in a rural Ugandan cohort.Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in UgandaTransmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI SubstudyEffect of HIV-1 subtypes on disease progression in rural Uganda: a prospective clinical cohort study.
P50
Q27320867-094D6969-1AC7-49EC-8D2E-A7323296F7B4Q28217042-A6C17D28-FB65-4554-A4BD-CC81E64A1295Q28254005-44E46B28-8133-4EA6-ADC1-1BB2F493E469Q28388716-C186B6E9-B90C-46F9-B146-E093D1E5078BQ28539131-D94A4A0D-64BF-4DAB-BB98-0236776DC7C1Q28545866-02EADA03-EF05-41B5-9125-027375C3405EQ28547717-8A4BB298-6919-4400-99B3-3240DAFCCB13Q28548288-B655452F-3E01-4C5F-B3B0-4C5676FDA2FBQ28551745-E2F9AEC8-8BED-426F-8F93-96DB2C228BBFQ28552624-5DC0B9FB-CC80-4852-A871-69FF71EA4BDFQ28654629-A9C50B57-CB27-4A57-A219-D0C7637336A8Q28658944-2B2C8FB9-0367-4DE3-8354-CE03BDDEF665Q28659915-2742D58B-B8EA-4758-B03A-775D2967B579Q28660329-76B3422F-7295-4043-9D06-92DA789CDD7CQ28661470-BB09EC48-5908-4C56-8EFF-AB91441A1C18Q30330292-81E2B640-6C30-4198-9403-FCCF46DF39C6Q30385577-6642BE46-D828-438F-9889-46B70154697EQ30393945-F855A9DC-99E4-4037-9A60-BF797A3CB3A4Q33389245-1C6B7FE3-FC7A-4BF1-8FAD-9B8F1EE89351Q33399724-B12FA7D7-6155-4665-90B5-066CE6E4FDBDQ33406262-2B83C063-3B64-4F07-9F0A-B6B3EC092737Q33589766-03306D78-2F33-4BD8-89D9-23EF1E3B71D2Q33603586-06887D14-D356-4CE2-B1FF-E8B96D91F9DBQ33631046-1083BC32-4DFC-464B-86B5-0F7BDE824232Q33637297-B5F3492E-F074-44D9-B1E7-BCCB8F4C991DQ33640397-882FD103-C37D-4929-B578-D5EF770C6059Q33647567-466A80A4-F9E3-41EA-AF28-C4DA54105165Q33715526-1AE9693E-4483-4847-9B38-5B50B058FFFEQ33778327-7CD656EF-FAF5-475D-9C9A-3D291AC76504Q33808848-9A41E4FD-23A3-474A-B050-D693F7479896Q33927434-0B1BFCD5-845E-4E52-9968-880B66157C68Q34037516-3AEA0476-9DCD-48B6-9EBC-C8C850680C34Q34068017-9FAFF1A1-74D8-4123-9BCD-FB1A00436E55Q34102202-53711D53-1989-4812-A4A0-195ADEF29071Q34229329-5952250F-2518-46ED-9D71-420C9EA792A1Q34374412-47771421-F167-4CDD-8708-3FD474C02910Q34587037-A7B1F43E-906C-4063-B7B2-3E5EA6BA410AQ34606742-E7985459-CD59-4B6F-8152-9E1B41E254C0Q34730855-880C7744-A9F4-424D-9CB9-614A198CC5C4Q34950563-2D20C3AA-DE73-4E6D-AAA3-BB5262509F30
P50
description
wetenschapper
@nl
name
Pontiano Kaleebu
@ast
Pontiano Kaleebu
@en
Pontiano Kaleebu
@es
Pontiano Kaleebu
@nl
بونتيانو كاليبو
@ar
type
label
Pontiano Kaleebu
@ast
Pontiano Kaleebu
@en
Pontiano Kaleebu
@es
Pontiano Kaleebu
@nl
بونتيانو كاليبو
@ar
prefLabel
Pontiano Kaleebu
@ast
Pontiano Kaleebu
@en
Pontiano Kaleebu
@es
Pontiano Kaleebu
@nl
بونتيانو كاليبو
@ar
P101
P19
P2031
1995-01-01T00:00:00Z
P21
P31
P569
1960-01-01T00:00:00Z